Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Announces Purchase Price for Notes

NEW YORK, Nov. 9 (GenomeWeb News) - PerkinElmer disclosed the purchase price for its previously announced tender offer after markets closed yesterday.


As GenomeWeb News reported yesterday afternoon, PerkinElmer received consents from its noteholders approving its cash tender offer for outstanding notes.


PerkinElmer anticipates Nov. 14 as the initial settlement date.


Holders who tender notes prior to the settlement date will receive total consideration per $1,000 principal amount of notes tendered of $1,119.64. This includes the consent payment of $20 and accrued and unpaid interest up to the payment date.


Holders who tender notes between the settlement date and expiration date of Nov.23, 9:00am, will receive total consideration per $1,000 principal amount of notes tendered of $1,118.65. This also includes the consent payment and accrued and unpaid interest.


The purchase price was calculated with the bid-side price of the US Treasury Note as indicated on Bloomberg screen PX5 at 2:00pm New York City time yesterday, the company said.


The company also said today that $269.9 million, or 99.6% of the aggregate outstanding principal amount of notes was validly tendered. The company had said 96% yesterday.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.